42 results on '"Almeida J."'
Search Results
2. PIN70 COST-EFFECTIVENESS OF SEASONAL VACCINATION WITH QUADRIVALENT INFLUENZA VACCINE IN PORTUGAL
3. PCN145 - COST-EFFECTIVENESS OF NINTEDANIB FOR THE TREATMENT OF NON-SMALL LUNG CANCER IN PORTUGAL
4. A Systematic Review of the Epidemiology of Alpha-Mannosidosis
5. Cost-Effectiveness of Trifluridine/Tipiracil for The Treatment of Metastatic Colorectal Cancer in Portugal
6. Clinical And Economic Impact of Treatment-Free Interval In Patients With Relapsed/Refractory Multiple Myeloma
7. Cost-Effectiveness of Pixantrone for the Third-/Fourth-Line Treatment of Aggressive Non-Hodgkin’s Lymphoma in Portugal
8. PSY26 - A Systematic Review of the Epidemiology of Alpha-Mannosidosis
9. High Therapeutic Efficiency With Ledipasvir/Sofosbuvir For The Treatment Of Genotype 1 Chronic Hepatitis C In Portugal
10. Pharmacoeconomics Of Ruxolitinib Therapy In Patients With Myelofibrosis
11. Ledipasvir / Sofosbuvir for The Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups
12. Therapeutic and Economic Value of Everolimus Plus Exemestane for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, Her2/Neu Negative Advanced Breast Cancer
13. PCN141 - Cost-Effectiveness of Trifluridine/Tipiracil for The Treatment of Metastatic Colorectal Cancer in Portugal
14. Upfront Overall Survival Modelling in Comparison to Real World Data: Lenalidomide for the Treatment of Multiple Myeloma Patients in South Korea
15. Cost-Effectiveness of Lenalidomide-Plus-Dexamethasone in Multiple Myeloma Patients Who Have Received at Least One Prior Therapy: A South Korean Perspective
16. Cost-Effectiveness Of Linaclotide: A Valuable Option In The Treatment Of Irritable Bowel Syndrome
17. PCN123 - Cost-Effectiveness of Pixantrone for the Third-/Fourth-Line Treatment of Aggressive Non-Hodgkin’s Lymphoma in Portugal
18. PSY46 - Clinical And Economic Impact of Treatment-Free Interval In Patients With Relapsed/Refractory Multiple Myeloma
19. PSS15 A New Insight Into Cost-Effectiveness Analyses in Atopic Dermatitis: The Tacrolimus 0.1% Ointment Versus Ciclosporin Comparison
20. PHP44 Public Financing of Medicines in Portugal (2007-2011): Accessibility to Medicinal Products with New Molecules or New Therapeutic Indications
21. PHP32 Understanding Accessibility for New Medicines Entering the Market Since 2007 in Portugal Using Survival Analysis
22. PHP33 The Use of Extreme Value Statistics in Assessing Long Decision Times in Public Funding of Medicines with New Molecules or Therapeutic Indications
23. PCN58 A Comprehensive Cost-Effectiveness Analysis of Lenalidomide for Multiple Myeloma Patients who Have Received at Least One Prior Therapy
24. PCN92 The Cost-Effectiveness of Nanoparticle Albumin-Bound Paclitaxel Compared to Solvent-Based Paclitaxel in Women with Metastatic Breast Cancer
25. PCN133 - Therapeutic and Economic Value of Everolimus Plus Exemestane for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, Her2/Neu Negative Advanced Breast Cancer
26. PCV96 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC STABLE ANGINA PATIENTS IN A FINNISH SETTING
27. PCV10 ECONOMIC VALUE OF RESTING HEART RATE AS AN INDEPENDENT CARDIOVASCULAR RISK FACTOR IN STABLE ANGINA PATIENTS
28. MH1 A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER—COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE
29. PCV97 COST-EFFECTIVENESS OF IVABRADINE IN PATIENTS WITH CHRONIC STABLE ANGINA IN A DUTCH SETTING
30. PGI21 - Cost-Effectiveness Of Linaclotide: A Valuable Option In The Treatment Of Irritable Bowel Syndrome
31. PCN20 - Cost-Effectiveness of Lenalidomide-Plus-Dexamethasone in Multiple Myeloma Patients Who Have Received at Least One Prior Therapy: A South Korean Perspective
32. PRM19 - Upfront Overall Survival Modelling in Comparison to Real World Data: Lenalidomide for the Treatment of Multiple Myeloma Patients in South Korea
33. PIN56 - Ledipasvir / Sofosbuvir for The Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups
34. PIN14 - High Therapeutic Efficiency With Ledipasvir/Sofosbuvir For The Treatment Of Genotype 1 Chronic Hepatitis C In Portugal
35. PCN151 - Pharmacoeconomics Of Ruxolitinib Therapy In Patients With Myelofibrosis
36. PGI21 Cost-Effectiveness Of Linaclotide: A Valuable Option In The Treatment Of Irritable Bowel Syndrome
37. PCN151 Pharmacoeconomics Of Ruxolitinib Therapy In Patients With Myelofibrosis
38. PCN133 Therapeutic and Economic Value of Everolimus Plus Exemestane for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, Her2/Neu Negative Advanced Breast Cancer
39. PIN56 Ledipasvir / Sofosbuvir for The Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Across Different Genotype 1 Clinical Subgroups
40. PCN20 Cost-Effectiveness of Lenalidomide-Plus-Dexamethasone in Multiple Myeloma Patients Who Have Received at Least One Prior Therapy: A South Korean Perspective
41. PRM19 Upfront Overall Survival Modelling in Comparison to Real World Data: Lenalidomide for the Treatment of Multiple Myeloma Patients in South Korea
42. PIN14 High Therapeutic Efficiency With Ledipasvir/Sofosbuvir For The Treatment Of Genotype 1 Chronic Hepatitis C In Portugal
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.